In a recent paper published in Oncogene, Tailler et al. 1 identified the cardiac glycoside ouabain as a potential antileukemic compound. They observed that ouabain was highly efficient in inhibiting the growth of human acute myeloid leukemia cells xenotransplanted in immunodeficient mice, without exerting significant toxicity on the host. The authors concluded that ouabain was a promising antileukemic agent whose activity should be evaluated in prospective clinical studies.
It has been known for some time that rodent cells are extremely more resistant than human cells to the cytotoxic effects of cardiac glycosides (both cardenolides and bufadienolides). 2 Indeed, rodent cells were found to be over 100 times more resistant than human cells to the cytotoxic activity of all tested cardiac glycosides, including ouabain. 2 This means that the anticancer effects induced by cardiac glycosides in mice harboring human cancer cells are probably due to interspecies differences in sensitivity and not to selective inhibition of tumor growth. In other words, the marked reduction in tumor growth observed when human cancer cells are xenografted into immune-deficient mice is probably caused by the ability of cardiac glycosides to kill human cells versus rodent cells rather than by their ability to kill cancer cells versus normal cells. We detected this experimental artifact in a PNAS paper, in which the cardiac glycoside digoxin was shown to induce a potent inhibition of tumor growth in mice xenografted with human cancer cells. 3, 4 Our Letter to the Editor failed to reach many authors, reviewers and editors, as numerous papers containing this probable experimental artifact have been published since then. 1, [5] [6] [7] [8] [9] [10] We propose the use of a panel of human cancer cell lines, human non-malignant cell lines and rodent cell lines to detect this experimental artifact and/or to further evaluate the cancer therapeutic potential of cardiac glycosides. Table 1 shows the cytotoxicity of the cardiac glycosides ouabain, digoxin and digitoxin against three human cancer cell lines, three human non-malignant cell lines from the same origin and two rodent cell lines. Data show that the rodent cells are approximately 1000 times more resistant than the human cells to the cytotoxic activity of these three cardiac glycosides, and that their selectivity toward the human cancer cells versus the human non-malignant cells is variable and not higher than 10-fold. Tailler et al. 1 observed that ouabain induced cytotoxic effects in human leukemia cells at concentrations between 100 and 1000 nM, and Table 1 shows that ouabain inhibits the growth of the three human non-malignant cell lines at concentrations between 29.4 and 60.8 nM. These data do not support the use of ouabain in patients with leukemia, and strongly suggest that the marked in vivo antileukemic activity observed when human leukemia cells were xenotransplanted into immunodeficient mice is an experimental artifact caused by the ability of ouabain to kill human cells selectively rather than by its ability to kill leukemia cells selectively. In contrast, we report that digitoxin inhibits the growth of the human A549 lung cancer cell line selectively and at concentrations below those commonly observed in the plasma of cardiac patients treated with this drug (20-33 nM), 11 an observation that deserves further investigation. 
